Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) last traded at $5.75. The firm’s performance so far in this year is 82.54%. The 200-day simple moving average is 67.73%. It is considered a key indicator by market analysts and traders for determining the long-term trend. The price mark in a market that coincides with it is recognized as a key support when price moves above the 200-day SMA or resistance when stock price is below this level.
As per recent filings, Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has an insider ownership of 17.22%.
Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has been storming Wall Street with promising press release. Recently, the firm reported that according to the March 2017 analysis commissioned by RetailMeNot and performed by Forrester Consulting, the firm’s mobile marketing solutions result in a 3-year, risk-adjusted ROI of 4.3x.
The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.
The Exponential Moving Average is a tool same as a simple moving average, with the only difference being a weighting factor used by EMA that exponentially declines from the recent data point. EMA analysis checks the averages for different period, including short term that is 5 days and 13 days, intermediate term for 20 days and long term of 50 days EMA. The bullish signals are received when they trade above trailing EMAs and below the prevailing price and vice versa. EMA signals include crossovers and EMA convergences The long term and short term EMA’s of 4.64 and 4.08 are lower than the current trading price suggesting a bullish pattern in both short term as well as long term. .
The relative strength index can be marked as a momentum oscillator that is able to read the velocity and magnitude of equity price changes. The current RSI is 71.20 suggesting a bullish price action.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) is all set to post its earnings on May 19. As per Zack’s analyst ratings, Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) presently has an average brokerage rating of . On a scale of 1 – 5, a rating of 2 or 1 would indicate a buy, and a 4 or 5 rating would signify a sell while a rating of 3 indicates a hold.
As such, while we consider Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) represents a convincing growth story exposed to different attractive markets, it would be enticing to see what it brings for long-term investors.